Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio is well-positioned with a strong cash position of $798.6M and a market value of $7.77B, supported by discounted cash flow analysis-based asset value and $772.6M in cash and investments. The company's potential approval and successful commercial launch of tinlarebant, its differentiated once daily oral tablet for treating degenerative retinal diseases, and an interim analysis of its Phase 3 PHOENIX trial expected in 2H26, provide potential upside for investors in the long-term, despite risks associated with clinical trials and regulatory approvals.

Bears say

Belite Bio is currently in a critical stage of drug development and regulatory submissions for their lead product candidate, tinlarebant. While they have achieved positive results in their Phase 3 DRAGON trial for patients with STGD1, their success in obtaining regulatory approval from the PMDA in Japan and the FDA in the US is not guaranteed. Additionally, there are significant risks associated with their product's commercial success due to potential competition and market size limitations. Despite having significant cash and investments, Belite Bio remains a high-risk investment due to uncertainties surrounding their drug's clinical efficacy and regulatory approvals.

BLTE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 6 analysts, BLTE has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $201.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $201.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.